Serum reverse T3 and amiodarone efficacy

R. J. Haberman, P. W. Ladenson, L. S.Cameron Griffith, E. P. Veltri

Research output: Contribution to journalArticlepeer-review


The use of serum reverse T3 (rT3) levels in the assessment of amiodarone efficacy is controverstal. We prospectivly studied 10 patients with frequent ventricular ectopy and symptomatic ventricular tachycardia (VT) treated with amiodarone. Serial 24‐h Holter monitor, thyroid function studies incliding serum rT3, and 12‐lead electrocardiogram were performed on each patient at baseline, and at 1, 4, 12, and 24 weeks of oal amiodarone therapy. Serial Holter moniotors on therapy were analysed for 100% suppression of VT, 90% suppression of couplets, and 85% suppression of ventricular ectopic beats (VEBs) compared with baseline Holter, defining patient groups VT−, Co−, and VEB−, respectively. Lack of arrhythmia suppression to this degree defined groups as VT+, Co+, and VEB+. These were no statistically significnat differneces in rT3 levels between VT+ and VT− groups, Co+ and Co− groups, or the VEB+ and VEB− groups. VT suppression could not be predicted at any rT3 level. We conclude than serum rT3 is an insensive means of assessing amiodarone efficacy.

Original languageEnglish (US)
Pages (from-to)140-144
Number of pages5
JournalClinical Cardiology
Issue number3
StatePublished - Mar 1989
Externally publishedYes


  • amiodarone
  • antiarrhythmia agents
  • thyroid

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Serum reverse T3 and amiodarone efficacy'. Together they form a unique fingerprint.

Cite this